FAILURE OF KETOCONAZOLE AS ANTI-ANDROGEN THERAPY IN NONRESECTABLE PRIMARY HEPATOCELLULAR-CARCINOMA
FAILURE OF KETOCONAZOLE AS ANTI-ANDROGEN THERAPY IN NONRESECTABLE PRIMARY HEPATOCELLULAR-CARCINOMA
复制标题
DOI：
10.1097/00004836-198812000-00016
复制
发表时间：
1988-12-01
影响因子：
2.9
通讯作者：
KORULA, J
中科院分区：
文献类型：
--
作者：
GUPTA, S;KORULA, J
由于无法切除的肝细胞癌（HCC）缺乏治疗方法，我们利用酮康唑的雄激素拮抗剂特性治疗了8例HCC患者，7例男性和1例女性，鉴于男性HCC的患病率较高，HCC似乎是雄激素依赖性的。通过症状分级、血清甲胎蛋白、肿瘤大小的改变和生存时间来确定对治疗的反应。没有患者出现任何明显的酮康唑副作用。没有出现症状改善，肿瘤大小百分比从38.6+/-12，平均+/-SEM增加到44.4+/-12，6名患者的平均生存期从诊断到死亡不到8周。抗雄激素治疗与酮康唑是无效的，在这些患者。
Lacking a treatment for nonresectable hepatocellular carcinoma (HCC), we have utilized the androgen antagonist properties of ketoconazole in treating eight patients, seven men and one woman, with HCC, which, in view of a higher prevalence of HCC in men, seems to be androgen dependent. Response to treatment was determined by grading symptoms, serum alphafetoprotein, alteration in tumor size, and duration of survival. No patient had any significant side-effects from ketoconazole. No symptomatic improvement occurred, percent tumor size increased from 38.6+/-12, mean+/-SEM, to 44.4+/-12, and mean survival in six patients who were followed until death was less than 8 weeks from diagnosis. Anti-androgenic therapy with ketoconazole was not effective in any of these patients.